(afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor – Business Wire

2 August 2024

157

(afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor Business Wire
FDA approves innovative T cell immunotherapy for rare soft-tissue cancer STAT
FDA signs off on Adaptimmune’s Tecelra as the first engineered cell therapy for a solid tumor FiercePharma
US FDA Approves Adaptimmune’s Gene Therapy for Rare Cancer U.S. News & World Report
Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor Morningstar